A detailed history of Ironwood Investment Management LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Ironwood Investment Management LLC holds 28,421 shares of KZR stock, worth $180,189. This represents 0.01% of its overall portfolio holdings.

Number of Shares
28,421
Previous 27,010 5.22%
Holding current value
$180,189
Previous $16,000 31.25%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.53 - $0.77 $747 - $1,086
1,411 Added 5.22%
28,421 $21,000
Q2 2024

Aug 16, 2024

SELL
$0.6 - $0.92 $601 - $921
-1,002 Reduced 3.58%
27,010 $16,000
Q1 2024

May 15, 2024

BUY
$0.8 - $1.05 $2,291 - $3,007
2,864 Added 11.39%
28,012 $25,000
Q4 2023

Feb 14, 2024

SELL
$0.72 - $1.15 $2,492 - $3,981
-3,462 Reduced 12.1%
25,148 $23,000
Q3 2023

Nov 16, 2023

SELL
$1.08 - $2.54 $14 - $33
-13 Reduced 0.05%
28,610 $34,000
Q2 2023

Aug 11, 2023

BUY
$2.31 - $3.06 $66,119 - $87,586
28,623 New
28,623 $70,000
Q1 2023

May 15, 2023

BUY
$3.13 - $7.31 $2,917 - $6,812
932 Added 3.21%
30,011 $93,000
Q4 2022

Jan 31, 2023

SELL
$6.39 - $8.8 $12,811 - $17,644
-2,005 Reduced 6.45%
29,079 $204,000
Q3 2022

Nov 14, 2022

BUY
$7.99 - $10.75 $599 - $806
75 Added 0.24%
31,084 $268,000
Q2 2022

Aug 12, 2022

BUY
$4.58 - $17.13 $164 - $616
36 Added 0.12%
31,009 $256,000
Q1 2022

May 10, 2022

BUY
$12.3 - $18.33 $3,837 - $5,718
312 Added 1.02%
30,973 $515,000
Q4 2021

Feb 10, 2022

BUY
$7.44 - $16.72 $228,117 - $512,651
30,661 New
30,661 $513,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $433M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Ironwood Investment Management LLC Portfolio

Follow Ironwood Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ironwood Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ironwood Investment Management LLC with notifications on news.